Dual checkpoint inhibition in gallbladder cancer: Bridging new hope with the need for biomarkers

Dual checkpoint blockade with nivolumab plus ipilimumab in patients with advanced, refractory gallbladder cancer showed activity in select patients in cohort 48 of the SWOG 1609 DART trial. Optimizing patient selection for this regimen will require validating predictive biomarkers of response and understanding the role of the regimen after chemoimmunotherapy in the frontline.